EUVIMEDEUVIMED entdecken
Open Access

Potential treatment benefits of a GLP‑1R antagonist in combination with immune checkpoint inhibitors in colorectal cancer

Zengqin Zhan, Chuncha Zhan, Lianqiao Li, Dan Lan, Guya Meng, Fan Chen

Oncology Letters · 10.02.2026 · 31 (4) · 1-13

DOI: 10.3892/ol.2026.15485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 10.02.2026. Verfasst von Zengqin Zhan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guangzhou Development District Hospital, Guangzhou, Guangdong 510700, P.R. China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Exendin 9–39T-cell-mediated cytotoxicitycolorectal cancerglucagon-like peptide-1 receptorimmune checkpoint inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Guangzhou Development District Hospital, Guangzhou, Guangdong 510700, P.R. China.
  • Department of General Practice, Tianyuan Community Health Service Center, Tianhe, Guangzhou, Guangdong 510000, P.R. China.
  • Department of Oncology, People's Hospital of Sandu County, Guizhou 558100, P.R. China.

Zitieren

APA

Zhan, Z., Zhan, C., Li, L., Lan, D., Meng, G., & Chen, F. (2026). Potential treatment benefits of a GLP‑1R antagonist in combination with immune checkpoint inhibitors in colorectal cancer. Oncology Letters, 31(4), 1-13. https://doi.org/10.3892/ol.2026.15485

Vancouver

Zhan Z, Zhan C, Li L, Lan D, Meng G, Chen F. Potential treatment benefits of a GLP‑1R antagonist in combination with immune checkpoint inhibitors in colorectal cancer. Oncology Letters. 2026;31(4):1-13. doi:10.3892/ol.2026.15485

BibTeX
@article{Zhan2026,
  author = {Zhan, Zengqin and Zhan, Chuncha and Li, Lianqiao and Lan, Dan and Meng, Guya and Chen, Fan},
  title = {Potential treatment benefits of a GLP‑1R antagonist in combination with immune checkpoint inhibitors in colorectal cancer},
  journal = {Oncology Letters},
  year = {2026},
  volume = {31},
  number = {4},
  pages = {1--13},
  doi = {10.3892/ol.2026.15485}
}
Kostenlos starten →